RecruitingPhase 4NCT01225913

Mechanism(s) of Airflow Limitation During Exacerbation of Asthma

Evaluation of Mechanism(s)Limiting Expiratory Airflow in Chronic, Stable Asthmatics Who Are Non-smokers


Sponsor

Gelb, Arthur F., M.D.

Enrollment

50 participants

Start Date

Oct 1, 2007

Study Type

INTERVENTIONAL

Conditions

Summary

The purpose of this study is to evaluate the site and mechanisms responsible for expiratory airflow limitation in chronic, treated, non-smoking, stable asthmatics with moderate to severe persistent expiratory airflow obstruction. Treatment will include inhaled corticosteroids and long acting beta2agonists. The investigators are interested in determining whether the large and/or small airways are the predominant site of airflow limitation. The investigators are also interested in determining whether intrinsic small airways obstruction and/or loss of lung elastic recoil is responsible for expiratory airflow limitation. The investigators are also interested to evaluate the role of varying doses of inhaled corticosteroids to suppress large and small airway inflammation using exhaled nitric oxide as surrogate markers of inflammation. For comparison purposes, spirometry and measurements of exhaled nitric oxide will also be obtained if possible during a naturally occurring exacerbation of asthma.


Eligibility

Min Age: 10 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This study examines what happens to airflow in the lungs during an asthma flare-up to better understand why breathing becomes so difficult, which could help develop more effective treatments. **You may be eligible if...** - You are between 10 and 80 years old - You have been diagnosed with asthma and are on stable treatment - You have lung function tests (spirometry) consistent with airflow limitation after using a rescue inhaler - You are a current non-smoker (fewer than 10 pack-years of smoking history) **You may NOT be eligible if...** - You are pregnant Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGfluticasone/salmeterol in all asthmatics

budesonide 80ug/formoterol 4.5ug, 2 inhalations bid X 20-60 days or fluticasone 100ug/salmeterol 50ug, 1 inhalation bid X 20-60 days

DRUGbudesonide/formoterol or fluticasone/salmeterol in all asthmatics

budesonide 160ug/formoterol 4.5ug, 2 inhalations bid or fluticasone 250ug/salmeterol 50ug, 1 inhalations bid


Locations(1)

Arthur F Gelb Medical Corporation

Lakewood, California, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT01225913


Related Trials